Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA / AKT1 / PTEN alterations, FAKTION data show.

Bora Lim rounds up the breast cancer studies that caught her attention at the virtual 2020 ASCO Annual Meeting, including the MONALEESA pooled ctDNA analysis and the BYLieve trial (7:04).

Suneel Kamath discusses the impact of time to treatment on the survival of rural breast cancer patients (5:31).

Combining pyrotinib instead of lapatinib with capecitabine is associated with significantly improved progression-free survival in patients who have received prior treatment for HER2-positive metastatic breast cancer, show phase 3 trial data.

Long-term follow-up of the TRAIN-2 study shows that patients with stage II or III HER2-positive breast cancer who receive neoadjuvant chemotherapy and dual HER2-blockade derive no survival benefit from the addition of anthracyclines.

Findings from the proof-of-principle Olaparib Expanded study indicate that patients with stage IV breast cancer and germline PALB2 or somatic BRCA1 / 2 mutations may benefit from olaparib treatment.

Individuals who present with metastatic breast cancer do not experience improvement in overall survival or other outcomes with early locoregional therapy for an intact primary tumor, according to ECOG-ACRIN 2108 trial findings.

Tucatinib, a selective HER2 kinase inhibitor, added to trastuzumab and capecitabine has demonstrated a survival benefit in patients with HER2-positive breast cancer and brain metastases in the HER2CLIMB trial, as presented at the virtual 2020 ASCO Annual Meeting.

A randomized trial and a cross-sectional analysis have found that remote patient monitoring had a positive impact on people with cancer during the COVID-19 pandemic, while a survey suggests that patients also find the approach favorable.

Jeremy Warner provides a comprehensive overview of the findings from the first 1018 patients with cancer and COVID-19 enrolled in the CCC19 registry (14:40).

Denise Yardley reports on the outcomes of participants with visceral metastases in the MONALEESA-3 and MONALEESA-7 trials of ribociclib for hormone receptor-positive, HER2-negative breast cancer (8:54).

Adjuvant treatment with trastuzumab emtansine does not improve outcome or reduce toxicity relative to that with a taxane plus trastuzumab in patients with HER2-positive early breast cancer, results of the phase 3 KAITLIN study show.

Seema Khan puts the results of the phase 3 study of locoregional therapy for de novo stage IV breast cancer in context of the two other studies that addressed the same research question (5:38).

The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.

Jame Abraham describes the design of a phase 1 trial now investigating the novel LIV-1-targeted antibody–drug ladiratuzumab vedotin in patients with metastatic breast cancer (3:43).

Nancy Lin presents the latest findings from the HER2CLIMB trial, reporting on the intracranial efficacy of tucatinib given alongside trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases (5:12).

Javier Cortes discusses the KEYNOTE-355 trial findings for pembrolizumab plus chemotherapy in patients with recurrent inoperable or metastatic triple-negative breast cancer (5:36).